PHARMA 4.0

Pharma 4.0, Thursday 1 March 2018

08:45

Organiser's Welcome Remarks

08:50

Chair's Opening Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng
09:00

Venture capital funding for the biotech industry: A case study

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important priorities than to invest in early stage companies, the role of the VC becomes even more crucial and necessary for success. Investigate how VC helps biotech to take flight in the competitive generics and biosimilar-focused Asia market.
 
John Connolly
09:20

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
 
Panel discussion
09:40

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?
 
Joe Zhou, Chief Executive Officer, Genor BioPharma, Walvax Group
10:20

Speed Networking

10:30

Exhibition Visit & Networking Refreshments

Pharma 4.0: Clinical Trials

Pharma 4.0
10:55

Chair's Opening Remarks

Shwen Gwee
Pharma 4.0
11:00

Digital trends impacting clinical trials

  • An overview on how data can transform pharma trials, from recruiting patients to real time drug performance evaluation
  • Using digital tools to optimise site selection, identification and engagement
  • Enhancing patient recruitment and compliance in trials conduction
Pharma 4.0
11:20

The Internet of Medical Things (IoMT): Big data in electronic disease surveillance, modelling and beyond

  • Generating and collecting electronic data and passive records from internet, mobile phones etc.
  • Designing participatory platforms and interactive digital infrastructure to allow better data collection
  • Combining e-health record (EHR), traditional and non-traditional digital data in disease surveillance, prediction and modelling
Oscar Luo
Pharma 4.0
11:40

Big data & AI in digital rare disease patient recruitment

  • Using supercomputer and AI in matching patients to trials
  • Aligning your strategy & planning with R&D objectives
  • Evaluating and improvising planned digital clinical trial strategy
12:00

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 1: Upcoming vaccines in Asia and how to prepare for it

Table 2: Sustainable vaccines strategies in global health, high-income and private sector

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: What can we learn fromCAR-T, PDL1, Cancer Vaccines successes, and what’s next in Asia?

Table 6: CRISPR & Precision medicine

Table 7: AI& Big data in drug discovery

Table 8: IoT and blockchain in clinical studies

Table 9: Pricing & Reimbursement strategies in Asia

Table 10: What can we do to reconcile our diversified pharma regulations in Asia?

Table 11: Bringing it together: Roles of Patient, Pharma, Hospital and Government in Drug Development

12:50

Exhibition Visit & Networking Lunch

Pharma 4.0: Drug Discovery

Pharma 4.0
14:10

Chair's Opening Remarks

Pharma 4.0
14:20

Fast-tracking drug discovery with supercomputers and artificial Intelligence (AI)

  • Using supercomputers and AI to automate virtual drug screening
  • Machine learning and pattern analysis in developing therapeutic treatments
  • Discussing the potential limitations of AI in drug discovery, and how we can overcome them
Pharma 4.0
14:40

Moving towards personalised medicine: Using big data to predict and customise treatment

  • Using digital to deliver better patient outcomes
  • Embracing digital reporting for stronger performance across key R&D capabilities
  • Addressing the potential compliance and cybersecurity risks in R&D digitalisation
Woong Yang Park
Pharma 4.0
15:00

Genome data mining and analysis for new drug discovery

  •     Identifying key gaps between current clinical trial methods with personalised treatment  
  •     Exploring key methods in genomics data mining and matching with patients to identify personalised treatment 
  •     Case study from Samsung Genomic Institute on the pathway towards personalised treatment
15:20

Exhibition Visit & Networking Refreshments

Pharma 4.0: Manufacturing & Supply Chain

Pharma 4.0
16:00

IoT in Pharma manufacturing: What have we learnt so far?

  • Using IoT and emerging tech for predictive maintenance
  • Optimising real time monitoring to improve pharma manufacturing
  • Case study: Lessons learnt from implementing IoT in pharma manufacturing
Pharma 4.0
16:20

Better decision making with big data analytics

  • Making sense of huge data volumes when using data analytics
  • Building real-time analysis capabilities for useful information collected from variable sources
  • Using big data in production lines to increase maintenance efficiency, improve availability and optimise maintenance costs
Pharma 4.0
16:40

Asset management and fleet tracking with IoT

  • Achieving greater visibility of products with multiple sensors on packages, trailers, warehouses and more
  • Enabling real time monitoring from pick up to delivery
  • Real-time track and trace to maximise product integrity
17:00

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 17/Nov/17 11:05